Incyte Stock News

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce reliance on Jakafi. The EPS miss is mostly related to elevated R&D spending, which will be critical to ease investors' fears about a potential loss of revenue from Jakafi in the coming years.

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be webcast live and can ...

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Incyte Corporation (NASDAQ:INCY ) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President,...

Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs.